AIMS: Neurologic impairment following ischemic injury complicates the quality of life for stroke survivors. Xenon (Xe) has favorable neuroprotective properties to modify stroke. Xe delivery is hampered by a lack of suitable administration strategies. We have developed Xe-containing echogenic liposomes (Xe-ELIP) for systemic Xe delivery. We investigated the time window for Xe-ELIP therapeutic effect and the most efficacious dose for neuroprotection. Molecular mechanisms for Xe neuroprotection were investigated. METHODS: Xenon-containing echogenic liposomes were created by a previously developed pressurization-freezing method. Following right middle cerebral artery occlusion (2 h), animals were treated with Xe-ELIP at 2, 3, or 5 h to determine time window of therapeutic effect. The neuroprotectant dosage for optimal effect was evaluated 3 h after stroke onset. Expression of brain-derived neurotrophic factor (BDNF), protein kinase B (Akt), and mitogen-activated protein kinases (MAPK) was determined. RESULTS: Xenon-containing echogenic liposomes administration for up to 5 h after stroke onset reduced infract size. Treatment groups given 7 and 14 mg/kg of Xe-ELIP reduced infarct size. Behavioral outcomes corresponded to changes in infarct volume. Xe-ELIP treatment reduced ischemic neuronal cell death via activation of both MAPK and Akt. Elevated BDNF expression was shown following Xe-ELIP delivery. CONCLUSION: This study demonstrates the therapeutic efficacy of Xe-ELIP administered within 5 h after stroke onset with an optimal dosage range of 7-14 mg/kg for maximal neuroprotection.
AIMS: Neurologic impairment following ischemic injury complicates the quality of life for stroke survivors. Xenon (Xe) has favorable neuroprotective properties to modify stroke. Xe delivery is hampered by a lack of suitable administration strategies. We have developed Xe-containing echogenic liposomes (Xe-ELIP) for systemic Xe delivery. We investigated the time window for Xe-ELIP therapeutic effect and the most efficacious dose for neuroprotection. Molecular mechanisms for Xe neuroprotection were investigated. METHODS:Xenon-containing echogenic liposomes were created by a previously developed pressurization-freezing method. Following right middle cerebral artery occlusion (2 h), animals were treated with Xe-ELIP at 2, 3, or 5 h to determine time window of therapeutic effect. The neuroprotectant dosage for optimal effect was evaluated 3 h after stroke onset. Expression of brain-derived neurotrophic factor (BDNF), protein kinase B (Akt), and mitogen-activated protein kinases (MAPK) was determined. RESULTS:Xenon-containing echogenic liposomes administration for up to 5 h after stroke onset reduced infract size. Treatment groups given 7 and 14 mg/kg of Xe-ELIP reduced infarct size. Behavioral outcomes corresponded to changes in infarct volume. Xe-ELIP treatment reduced ischemic neuronal cell death via activation of both MAPK and Akt. Elevated BDNF expression was shown following Xe-ELIP delivery. CONCLUSION: This study demonstrates the therapeutic efficacy of Xe-ELIP administered within 5 h after stroke onset with an optimal dosage range of 7-14 mg/kg for maximal neuroprotection.
Authors: Shaoling Huang; Andrew J Hamilton; Susan D Tiukinhoy; Ashwin Nagaraj; Bonnie J Kane; Melvin Klegerman; David D McPherson; Robert C MacDonald Journal: Cell Mol Biol Lett Date: 2002 Impact factor: 5.787
Authors: Daqing Ma; Mahmuda Hossain; Garry K J Pettet; Yan Luo; Ta Lim; Stanislav Akimov; Robert D Sanders; Nicholas P Franks; Mervyn Maze Journal: J Cereb Blood Flow Metab Date: 2006-02 Impact factor: 6.200
Authors: Himanshu Shekhar; Arunkumar Palaniappan; Tao Peng; Maxime Lafond; Melanie R Moody; Kevin J Haworth; Shaoling Huang; David D McPherson; Christy K Holland Journal: Neurotherapeutics Date: 2019-07 Impact factor: 7.620
Authors: Melvin E Klegerman; Melanie R Moody; Jermaine R Hurling; Tao Peng; Shao-Ling Huang; David D McPherson Journal: Rapid Commun Mass Spectrom Date: 2017-01-15 Impact factor: 2.419
Authors: Felix Ulbrich; Nils Schallner; Mark Coburn; Torsten Loop; Wolf Alexander Lagrèze; Julia Biermann; Ulrich Goebel Journal: PLoS One Date: 2014-12-23 Impact factor: 3.240
Authors: Yi-Feng Miao; Tao Peng; Melanie R Moody; Melvin E Klegerman; Jaroslaw Aronowski; James Grotta; David D McPherson; Hyunggun Kim; Shao-Ling Huang Journal: Sci Rep Date: 2018-01-11 Impact factor: 4.379